For research and educational purposes only. Not intended for human consumption.
KLOW Protocol
Limited Research- •Four-peptide regenerative stack
- •GHK-Cu + TB-500 + BPC-157 + KPV
- •Anti-inflammatory + healing synergy
Four-Peptide Regenerative Blend | GHK-Cu + TB-500 + BPC-157 + KPV
Overview
What is KLOW Protocol?
KLOW is a research peptide combination that builds upon the GLOW protocol by adding KPV for enhanced anti-inflammatory effects. This 80mg blend typically contains 50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, and 10mg KPV in a 5:1:1:1 ratio. While individual components have varying levels of research support, no clinical trials have examined this specific four-peptide combination. The protocol remains investigational with theoretical benefits based on complementary mechanisms.
Key Benefits
Theoretical synergistic effects from four peptides - tissue repair, anti-inflammation, cellular regeneration. KPV may reduce injection site reactions compared to GLOW. Single injection versus four separate peptides for convenience.
Mechanism of Action
Each peptide contributes different mechanisms: GHK-Cu modulates genes and stimulates collagen, TB-500 enhances cell migration, BPC-157 upregulates growth factors, KPV inhibits NF-κB for anti-inflammatory effects.
Molecular Information
Pharmacokinetics
Research Indications
Multi-Modal Healing
Addresses tissue repair through multiple complementary pathways.
Enhanced Tolerability
KPV may reduce injection site reactions compared to GLOW protocol.
Convenience Factor
Single injection versus four separate peptides.
Research Protocols
Disclaimer: No clinical trials have examined this specific four-peptide combination. Individual components have varying levels of research support. FDA has not approved any component for therapeutic use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Common Research Protocol | 3.2mg total (2mg GHK-Cu, 400mcg each TB500/KPV/BPC-157) | Once daily | Subcutaneous |
| Starter/Titration Protocol | 2mg total (1.25mg GHK-Cu, 250mcg each TB500/KPV/BPC-157) | Once daily | Subcutaneous |
| Cycling Protocol | As above | 4-6 weeks on, 2-4 weeks off | Subcutaneous |
Timing: Evening dosing is common practice but not based on research. Some prefer morning administration.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean vial top with alcohol pad
Add 2-5mL bacteriostatic water (4mL creates 20mg/mL)
Gently swirl - do not shake
Solution should be clear to slightly cloudy
Label with date and concentration
Store in refrigerator immediately
Use within 4-6 weeks
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Third-party testing
Look for Janoshik or similar analytical verification.
Reputable research supplier
Established vendors with quality control processes.
Research-only status
Not approved for human use - research purposes only.
Batch variability
Ratios and purity may vary between batches.
No COA provided
Avoid vendors without certificates of analysis.
What to Expect
- •Individual responses vary widely with no predictable timeline
- •Some users report reduced inflammation within days
- •Wound healing effects may take 2-4 weeks if they occur
- •No clinical data exists to set realistic expectations
- •Community polls: 835 responses, 57% currently using, 44% would definitely recommend
Side Effects & Safety
Side Effects
- •No safety studies on four-peptide combination
- •Individual peptides generally well-tolerated in research
- •Injection site reactions common (36% of users) even with KPV
- •Long-term effects completely unknown
- •Quality and contamination risks in unregulated market
When to Stop
- •Adverse effects
- •Signs of infection
- •Unusual symptoms
- •As directed by provider
References
3 StudiesIndividual Component Research - GHK-Cu
Human studies | Various protocols | 40+ years research | Wound healing, anti-aging, gene modulation
GHK-Cu has extensive research showing beneficial effects, but studies used GHK-Cu alone, not in combination.
BPC-157 Limited Human Data (2020)
Human pilot | 12 patients | Interstitial cystitis | 10 of 12 complete resolution
One small pilot study showed 10 of 12 patients achieved complete resolution of symptoms. Most BPC-157 research remains in animal models.
No Published Studies on KLOW Combination
No clinical trials | No safety studies | No peer-reviewed research
Despite vendor claims and user reports, no scientific studies have examined the safety or efficacy of the four-peptide KLOW combination.
Quick Start Guide
Research Disclaimer
KLOW Protocol is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving KLOW Protocol must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of KLOW Protocol for any purpose. Consult qualified professionals for any research applications.